Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$26.21 USD
+0.22 (0.85%)
Updated May 13, 2024 04:00 PM ET
After-Market: $26.19 -0.02 (-0.08%) 5:16 PM ET
4-Sell of 5 4
A Value F Growth C Momentum C VGM
Price, Consensus and EPS Surprise
IART 26.21 +0.22(0.85%)
Will IART be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IART based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IART
Deciphering Integra (IART) International Revenue Trends
Integra's (IART) Q1 Earnings Match Estimates, Margins Down
IART: What are Zacks experts saying now?
Zacks Private Portfolio Services
Integra (IART) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Earnings Preview: Integra LifeSciences (IART) Q1 Earnings Expected to Decline
Other News for IART
Integra LifeSciences to Present at the 2024 Bank of America Healthcare Conference
Integra LifeSciences: Expansion, Audits, and Share Repurchase Plan
Integra Lifesciences (IART) Receives a Sell from J.P. Morgan
Target upgraded, CVS downgraded: Wall Street's top analyst calls
Oppenheimer cuts Integra to perform, cites Boston plant delays